Stay updated with breaking news from Lobo Genetics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TORONTO, ON / ACCESSWIRE / February 8, 2022 / Novamind Inc. , a leading mental health company specialized in psychedelic medicine, is pleased to announce that Prakash Gowd has been appointed... | February 8, 2022
Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test HaluGen's DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry's first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc. ("HaluGen"), and that it is...
Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences Vancouver, British Columbia--(Newsfile Corp. - February 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (" Entheon" or the " Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides a production update on HaluGen Life Sciences Inc. (" HaluGen"), a wholly-owned subsidiary of Entheon, which is in the business of developing and commercializing a genetic test designed to identify specific DNA biomarkers in order to gauge the risk and potential of adverse re...
Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc. Vancouver, British Columbia--(Newsfile Corp. - January 14, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (" Entheon" or the " Company") is pleased to announce that the Company completed its acquisition of HaluGen Life Sciences Inc. (" HaluGen"), a biotech company in the business of developing and commercializing a pre-screening test to identify genetic markers predictive of an individual's reaction to hallucinogenic drugs. The Company acquired 100% of the issued and outstanding common shares in the capita...